TA-606
TA-606 is a potent and orally active angiotensin II-receptor antagonist. TA-606 shows antihypertensive efficacy. TA-606 can be used for hypertension research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 190602-72-3
- Fòrmula: C33H40ClN7O6
- Peso molecular:666.17
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas Angiotensin Receptor
More
Actividad biológica
Descripciòn
IC50 & Target
|
AT2 Receptor |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 190602-72-3
-
Peso molecular 666.17
-
Fòrmula C33H40ClN7O6
-
SMILES
CC(N1C(C2=C(CC1)N=C(N2CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5)CCC)C(OCOC(OC(CC)CC)=O)=O)=O.Cl
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocolo
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
TA-606 Related Classifications
HY-123226 Related Classifications
Powered by Bioz